Precigen [PGEN] vs Adaptive [ADPT] Detailed Stock Comparison
Precigen
NASDAQ
Loading...
Adaptive
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Precigen wins in 8 metrics, Adaptive wins in 10 metrics, with 0 ties. Adaptive appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Precigen | Adaptive | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -8.89 | -12.04 | Adaptive |
| Price-to-Book Ratio | -33.69 | 11.01 | Precigen |
| Debt-to-Equity Ratio | -0.14 | 121.39 | Precigen |
| PEG Ratio | 0.15 | 0.27 | Precigen |
| EV/EBITDA | -11.55 | -19.44 | Adaptive |
| Profit Margin (TTM) | -8.71% | -59.07% | Precigen |
| Operating Margin (TTM) | -3,254.32% | -42.52% | Adaptive |
| Return on Equity | -668.03% | -57.60% | Adaptive |
| Return on Assets (TTM) | -67.44% | -14.00% | Adaptive |
| Free Cash Flow (TTM) | $-76.76M | $-98.88M | Precigen |
| 1-Year Return | 260.34% | 167.49% | Precigen |
| Price-to-Sales Ratio (TTM) | 249.91 | 9.65 | Adaptive |
| Enterprise Value | $1.06B | $2.00B | Adaptive |
| EV/Revenue Ratio | 244.45 | 9.74 | Adaptive |
| Gross Profit Margin (TTM) | -27.57% | 69.43% | Adaptive |
| Revenue per Share (TTM) | $0 | $1 | Adaptive |
| Earnings per Share (Diluted) | $-0.41 | $-0.81 | Precigen |
| Beta (Stock Volatility) | 1.87 | 1.93 | Precigen |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Precigen vs Adaptive Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Precigen | 14.84% | 42.18% | 175.00% | 200.72% | 138.86% | 287.04% |
| Adaptive | 2.93% | -0.31% | 23.46% | 47.06% | 54.39% | 110.02% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Precigen | 260.34% | 69.23% | -32.58% | -91.06% | -85.63% | -85.63% |
| Adaptive | 167.49% | 24.05% | -68.15% | -73.08% | -73.08% | -73.08% |
Performance & Financial Health Analysis: Precigen vs Adaptive
| Metric | PGEN | ADPT |
|---|---|---|
| Market Information | ||
| Market Cap | $1.08B | $1.98B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 25,722,040 | 1,885,620 |
| 90 Day Avg. Volume | 10,564,153 | 1,989,907 |
| Last Close | $4.18 | $13.00 |
| 52 Week Range | $0.65 - $4.21 | $3.98 - $13.40 |
| % from 52W High | -0.71% | -2.95% |
| All-Time High | $69.45 (Aug 03, 2015) | $71.25 (Jan 18, 2021) |
| % from All-Time High | -93.98% | -81.75% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.19% | 0.36% |
| Quarterly Earnings Growth | 0.19% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | -0.09% | -0.59% |
| Operating Margin (TTM) | -32.54% | -0.43% |
| Return on Equity (TTM) | -6.68% | -0.58% |
| Debt to Equity (MRQ) | -0.14 | 121.39 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-0.12 | $1.18 |
| Cash per Share (MRQ) | $0.20 | $1.30 |
| Operating Cash Flow (TTM) | $-66,278,000 | $-80,470,000 |
| Levered Free Cash Flow (TTM) | $-48,459,376 | $-18,756,124 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Precigen vs Adaptive
| Metric | PGEN | ADPT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -8.89 | -12.04 |
| Forward P/E | -16.55 | -13.83 |
| PEG Ratio | 0.15 | 0.27 |
| Price to Sales (TTM) | 249.91 | 9.65 |
| Price to Book (MRQ) | -33.69 | 11.01 |
| Market Capitalization | ||
| Market Capitalization | $1.08B | $1.98B |
| Enterprise Value | $1.06B | $2.00B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 244.45 | 9.74 |
| Enterprise to EBITDA | -11.55 | -19.44 |
| Risk & Other Metrics | ||
| Beta | 1.87 | 1.93 |
| Book Value per Share (MRQ) | $-0.12 | $1.18 |
Financial Statements Comparison: Precigen vs Adaptive
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PGEN | ADPT |
|---|---|---|
| Revenue/Sales | $1.34M | $52.44M |
| Cost of Goods Sold | $1.10M | $16.98M |
| Gross Profit | $241,000 | $35.46M |
| Research & Development | $10.48M | $24.20M |
| Operating Income (EBIT) | $-22.60M | $-29.60M |
| EBITDA | $-21.04M | $-22.19M |
| Pre-Tax Income | $-54.15M | $-29.83M |
| Income Tax | $0 | N/A |
| Net Income (Profit) | $-54.15M | $-29.83M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PGEN | ADPT |
|---|---|---|
| Cash & Equivalents | $6.06M | $50.65M |
| Total Current Assets | $84.60M | $256.49M |
| Total Current Liabilities | $23.99M | $87.81M |
| Long-Term Debt | $4.49M | $76.44M |
| Total Shareholders Equity | $-14.06M | $190.22M |
| Retained Earnings | $-2.14B | $-1.33B |
| Property, Plant & Equipment | $21.84M | $88.43M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PGEN | ADPT |
|---|---|---|
| Operating Cash Flow | $-49.42M | $-18.25M |
| Capital Expenditures | $-622,000 | $-1.26M |
| Free Cash Flow | $-16.95M | $-29.74M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | $-355,000 | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PGEN | ADPT |
|---|---|---|
| Shares Short | 28.83M | 9.93M |
| Short Ratio | 9.77 | 5.90 |
| Short % of Float | 0.17% | 0.08% |
| Average Daily Volume (10 Day) | 25,722,040 | 1,885,620 |
| Average Daily Volume (90 Day) | 10,564,153 | 1,989,907 |
| Shares Outstanding | 292.87M | 147.77M |
| Float Shares | 150.47M | 117.37M |
| % Held by Insiders | 0.10% | 0.02% |
| % Held by Institutions | 0.67% | 0.98% |
Dividend Analysis & Yield Comparison: Precigen vs Adaptive
| Metric | PGEN | ADPT |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |